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Abstract 
Diabetes is an established risk factor for pancreatic cancer (PaC), together with obesity, Western 
diet, and tobacco smoking. The common mechanistic link might be the accumulation of advanced 
glycation endproducts (AGEs), which characterizes all the above disease conditions and unhealthy 
habits. Surprisingly, however, the role of AGEs in PaC has not been examined yet, despite the 
evidence of a tumor-promoting role of RAGE, the receptor for AGEs. Here, we tested the 
hypothesis that AGEs promote PaC through RAGE activation. To this end, we investigated the 
effects of the AGE Nε-carboxymethyllysine (CML) in human pancreatic ductal adenocarcinoma 
(PDA) cell lines and in a mouse model of Kras-driven PaC interbred with a bioluminescent model 
of proliferation. Tumor growth was monitored in vivo by bioluminescence imaging and confirmed 
by histology. CML promoted PDA cell growth and RAGE expression, in a concentration- and time-
dependent manner, and activation of downstream tumorigenic signaling pathways. These effects 
were counteracted by RAGE antagonist peptide (RAP). Exogenous AGE administration to PaC-
prone mice induced RAGE upregulation in pancreatic intraepithelial neoplasias (PanINs) and 
markedly accelerated progression to invasive PaC. At 11 weeks of age (6 weeks of CML treatment), 
PaC was observed in 8/11 (72.7%) of CML-treated versus 1/11 (9.1%) of vehicle-treated (Ctr) 
mice. RAP delayed PanIN development in Ctr mice but failed to prevent PaC promotion in CML-
treated mice, likely due to competition with soluble RAGE for binding to AGEs and/or 
compensatory upregulation of the RAGE homolog CD166/ALCAM, which favored also tumor 
spread. These findings indicate that AGEs modulate the development and progression of PaC 
through receptor-mediated mechanisms and might be responsible for the additional risk conferred 
by diabetes and other conditions characterized by increased AGE accumulation. Finally, our data 
suggest that an AGE reduction strategy, instead of RAGE inhibition, might be suitable for risk 
management and prevention of PaC. 
Key words:  pancreatic cancer, Kras mutation, advanced glycation endproducts, RAGE, diabetes, 
bioluminescence imaging. 
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Introduction 
Diabetes mellitus (DM), the prevalence of which is expected to increase dramatically in the next 
years (1), has been identified as a risk factor for a variety of malignancies, including pancreatic 
cancer (PaC) (2). The incidence of PaC continues to increase and it is predicted to become the 
second cause of cancer-related deaths in the US by 2030 (3). Since no effective therapy is available 
for the majority of patients and the 5-year survival is less than 7% (3), it is important to focus on 
prevention by eliminating risk factors  
Studies designed to unravel the mechanistic link between DM and PaC are complicated by the 
fact that type 2 DM, the most common form of DM, could promote PaC through a variety of 
factors, including hyperglycemia itself, dyslipidemia, chronic inflammation, and insulin 
resistance/hyperinsulinemia (4-8).  Recently, a tumor-promoting role has been suggested for the 
receptor for advanced glycation endproducts (RAGE), a single transmembrane receptor of the 
immunoglobulin superfamily. Ablation/blockade of this receptor was shown to slow down PaC 
development (9,10) by delaying progression of pancreatic intraepithelial neoplasia (PanIN) (10). 
Moreover, RAGE was found to regulate crosstalk between pro-survival pathways in pancreatic 
ductal adenocarcinoma (PDA) cells (11). RAGE interacts with multiple exogenous and endogenous 
ligands to induce inflammation (12) and is expressed in cell types implicated in tumor formation 
(13). As such, RAGE has been linked to cancer development/progression by facilitating the 
maintenance of a chronic inflammatory state (14) and/or promoting tumor growth (15). More 
specifically, RAGE ligation activates nuclear factor (NF)-κB, a critical transcription factor 
transducing a variety of inflammatory signals (16) and up-regulating RAGE itself, since the gene 
encoding RAGE contains functional NF-κB binding elements (17). 
The name of RAGE derives from its ability to bind the advanced glycation end-products (AGEs).  
Though a role for AGEs has been tentatively proposed to explain the increased risk of various 
cancers (including PaC) in diabetic and obese individuals (18), surprisingly, their role in pancreatic 
carcinogenesis has never been investigated (19). AGEs are a heterogeneous group of compounds 
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(20) that accumulate in tissues of aging individuals and, at an accelerated rate, in diabetic and obese 
subjects, due to several mechanisms, including increased carbohydrate and lipid substrate 
availability, oxidative and non-oxidative conditions favoring the glycation process, and impaired 
detoxification (21). In addition to endogenous production, high-temperature processed foods and 
cigarette smoking are major environmental sources of AGEs (22,23), which might therefore be 
involved in the increased PaC risk associated with dietary and smoking habits (24). Consistently 
with the involvement of the AGE-RAGE axis in human PaC, a large prospective study reported that 
plasma levels of soluble RAGE (sRAGE), a truncated circulating form acting as a decoy receptor in 
preventing RAGE activation (25), were inversely associated with risk of PaC among Finnish male 
smokers (26). 
This study aimed at investigating the tumor-promoting role of Nε-carboxymethyllysine (CML), a 
major AGE found in vivo (27) and a known RAGE ligand (28), in a well-characterized genetically-
engineered mouse model of human PaC and in PDA cell lines.  
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Materials and methods 
Study design 
The in vitro study was designed to investigate the tumor-promoting effects of  CML on PDA cell 
lines by evaluating cell growth and the main tumorigenic pathways involved in PaC promotion. A 
secondary objective was to assess whether these effects were RAGE-mediated. 
The in vivo study was designed to evaluate the effect of CML on progression of early murine 
pancreatic neoplasia. The primary and secondary endpoints were the development of invasive PaC 
and development/progression of PanINs, respectively. The number of mice was not pre-specified. 
According to the Ethics Committee recommendation, to limit the number of animals, the 
experiments were stopped when it was sufficient to confirm or reject the working hypothesis in a 
statistically and clinically meaningful manner. Biological samples were recoded by a technician 
(CC, see Acknowledgements) at the time of collection and analyzed by investigators blinded to 
group assignment. The research protocol was approved by the National Ethics Committee for 
Animal Experimentation of the Italian Minister of Health (Authorization n. 1470/2015-PR). The 
animals were housed in single cages and cared according to standards articulated in the “Animal 
Research: Reporting of In Vivo Experiments” (ARRIVE) (https://www.nc3rs.org.uk/arrive-
guidelines) guidelines. 
Cell lines 
Human MIA PaCa-2 and PANC-1 (PDA) cells (Sigma-Aldrich, St.Louis, MO, USA) and the 
normal human pancreatic duct epithelial (HPDE) cell line HPDE-E6E76c7 (H6C7) ( provided by 
Dr. Maurizio Fanciulli, Regina Elena National Cancer Institute, Rome, Italy) were maintained in 
DMEM supplemented with 10% fetal bovine serum and incubated with native human serum 
albumin (HSA, Sigma-Aldrich; vehicle, Ctr) or CML-modified HSA (1 μg/mL to 100 μg/mL, 
CML) ± the S100P-derived RAGE antagonist peptide (RAP, Calbiochem, Merck KGaA, 
Darmstadt, Germany; 10 μmol/L, daily added). CML was prepared as previously reported (21,29). 
Characterization of CML preparations by 2,4,6-trinitrobenzene sulfonic acid (TNBSA) revealed that 
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13.2±2.1% and 14.7±2.4% of total free amino groups (lysine and arginine) in CML-HSA and CML-
MSA, respectively, were modified. This rate of modification was previously found to have an 
activity to bind RAGE (28), but not scavenger receptors (30) and is comparable to that detected in 
serum proteins of diabetic patients (31).  RAGE binding to the CML-MSA preparation used in the 
in vivo studies was confirmed in a functional ELISA (Supplementary Figure 1).  The RAP 
concentration was chosen on the ground of the available literature data (9). Detailed information on 
CML preparation, characterization, and RAGE-binding activity is provided as Supporting 
Information. 
Cell viability and proliferation 
Cell viability and proliferation were evaluated by cell count using Countess® Automated Cell 
Counter (Life Technologies Carlsbad, CA, USA) and a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based cell proliferation assay (Roche Diagnostics GmbH 
Mannheim, Germany). 
RAGE and molecular targets of tumorigenic signaling pathways in PDA cells 
The mRNA expression of the genes coding for (a) RAGE; (b) CD166/ activated leukocyte cell 
adhesion molecule (ALCAM), a close structural and functional homolog of RAGE (32); (c) nuclear 
factor of activated T-cells cytoplasmic 1 (NFATC1) and serine/threonine-protein kinase Pim-1 
(PIM1), two Signal Transducer and Activator of Transcription 3 (STAT-3) downstream targets 
which have been involved in inflammation-driven PaC (33); and (d) interleukin-6 (IL-6), the 
production of which was shown to be RAGE-dependent in KC mice (10) (AGER, ALCAM, 
NFATC1, PIM1, and IL6, respectively) was assessed by real-time (RT)-PCR using a StepOne Real-
Time PCR System and the TaqMan Gene Expression assays (Applied Biosystems Monza, Italy) 
listed in Supplementary Table 1 (34,35). 
Nuclear protein extracts were obtained from cells monolayers using the Nuclear Extract Kit 
(Active Motif Corp., Carlsbad, CA, USA). Nuclear protein levels of NF-κB p65, phosphorylated 
STAT3 (p-STAT3), NFATC1, and hypoxia-inducible factor 1 (HIF-1) α, which is involved in 
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RAGE-Kras promotion of PaC (10), were assessed by Western blot (see Supplementary Table 2 for 
antibodies). The DNA-binding activity of NF-κB/p65 and HIF-1α were assessed by the TransAM 
NFkB p65 and HIF-1 Kit, respectively (Active Motif Corp.). Details on RAGE neutralization 
experiments with an anti-RAGE antibody are provided as Supporting Information. 
Transgenic animal model 
The effect of CML administration on PaC development through RAGE activation was 
investigated in genetically-engineered mice Pdx1-Cre;LSL-KrasG12D/+ (KC mice) on a C57Bl/6 
background, that develop autochthonous lethal PaC in a pattern recapitulating human PDA with 
high fidelity (36). KC mice were interbred with MITO-Luc (for mitosis luciferase) reporter mice on 
a FVB background (37,38) to obtain KC-Mito (KCM) mice (see Supporting Information). 
Five-week old KCM mice were randomly assigned to treatment with daily i.p. injections of 30 
μg of native mouse serum albumin (MSA, Ctr) or CML-modified MSA (CML) (21). At this age, 
pancreatic parenchyma is histologically normal and early-stage PanINs are rarely observed (36,38). 
The treatment dose was chosen based on our previous data showing that this injection protocol 
results in a 2-to-3 fold increase in circulating and tissues AGE levels (21,39), similar to that 
observed in experimentally diabetic mice (29,34,40,41). We subjected Ctr and CML-treated mice to 
longitudinal in vivo BLI imaging and manual palpation of the abdomen to monitor tumor 
development. Additional groups of KCM mice were treated with RAP at the dose of 100 μg/day (9) 
in addition to native MSA (Ctr+RAP) or CML-MSA (CML+RAP). 
In vivo imaging of cell proliferation in PaC 
Starting from the fifth week of age, in vivo imaging (37,38) was carried out every other week as 
previously reported (38). Briefly, 10 min after administration of D-luciferin (75 mg/kg body weight, 
i.p.; Perkin Elmer, Hopkinton, MA, USA), photon emission from the different body areas was 
acquired for 5 min and analyzed by a CCD camera (Xenogen IVIS Lumina System, Perkin Elmer). 
A specific region of interest (ROI) corresponding to the abdominal area occupied by the pancreas 
was manually selected and light emission from this ROI was evaluated with a Living Image 
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Software (Caliper Life Sciences, Perkin Elmer). Data were expressed as 
photon/second/cm2/steradiant (p/s/cm2/sr). 
Ex vivo imaging 
At the end of treatment, mice were anesthetized for the last in vivo imaging session and then 
euthanized by cervical dislocation. Pancreas was dissected and exposed to the CCD camera for 5 
minutes for photon emission assessment. 
Next, samples were partly frozen and kept at -80°C for molecular analysis and partly embedded 
in paraffin for histological analysis and immunohistochemistry (IHC). 
Pancreas histology 
At least six 4 μm-thick non-serial pancreatic sections were stained with hematoxylin and eosin, 
examined to confirm the presence of cancer or grade dysplastic ducts according to previously 
established criteria (36). 
The KCM, as well as KC mice, develop with complete penetrance ductal lesions identical to all 
three stages of human PanINs (36,42). Number of low-grade (PanIN-1A/B) and high-grade (PanIN-
2/3) dysplastic ducts were counted and expressed as a percentage of total ducts in the specimen 
(10). 
Pancreatic protein levels of RAGE and CD166/ALCAM, co-localization of RAGE with CML, 
and phosphorylation status of STAT3 
Pancreatic tissue distribution of RAGE and CD166/ALCAM was analyzed by IHC. Co-
localization of RAGE and CML was analyzed by dual label immunofluorescence, as described in 
the Supporting Information. Pancreatic protein levels of p-STAT3, RAGE, and CD166/ALCAM 
were assessed by Western blot (see Supplementary Table 2 for antibodies). 
For Western blot analysis, proteins were separated on a TGX Stain-Free Gel (Bio-Rad 
Laboratories, Hercules, California, USA), as detailed in the Supporting Information. 
Serum levels of the AGE CML, sRAGE and IL-6 
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Serum levels of CML, sRAGE, and IL-6 were assessed using ELISA kits (Cell Biolabs Inc. San 
Diego, CA, USA, for CML; R&D Systems, Minneapolis, MN, USA, for sRAGE and IL-6) (34,35). 
Lack of interference of circulating sRAGE and RAP with CML assays, and of CML and RAP 
with sRAGE assay was verified by adding increasing concentrations of each of these ligands to 
serum prior to perform the ELISAs (Supplemental Figure 2). Details of the experimental procedure 
are provided as Supporting Information. 
Statistical analysis 
Results are expressed as mean±SD and/or percentage.  
Differences between cell types/treatments or animal groups were assessed using the Student’s t 
test or the one-way ANOVA followed by the Student-Newman-Keuls test for multiple comparisons, 
as appropriate. Differences among animal groups in PaC prevalence at 11 weeks of age were 
assessed using the Fisher's exact test to compute a P-value from a contingency table. A P-value 
<0.05 was considered significant. 
All statistical tests were performed on raw data, using SPSS 13.0 statistical software. 
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Results 
The AGE CML promotes PDA cell proliferation and induces RAGE up-regulation 
CML promoted proliferation of Mia PaCa-2 cells in a time- and concentration-dependent manner 
(Figure 1A-B). A dose-dependent induction of proliferation was observed also in PANC-1 cells, 
peaking at 10 μg/mL (Figure 1C), whereas HPDE cells responded only at the lowest concentration 
tested (Figure 1D). 
Induction of proliferation was accompanied by increased RAGE expression in all three cell lines 
(Figure 1A-D). Interestingly, the CML concentration range with a positive dose-response 
relationship for proliferation at 24 hrs correlated with baseline RAGE expression (Figure 1E). 
AGE/RAGE axis modulates tumorigenic pathways involved in PaC 
CML treatment increased NK-κB p65 protein level and activation (Figure 2A-B) and p-STAT3 
nuclear content (Figure 2A) and induced the transcriptional activity of the STAT3 target genes 
NFATC1 and PIM1 (Figure 2C). 
RAP treatment counteracted all the molecular events elicited by CML and completely prevented 
CML-induced proliferation of PDA cells (Figure 2D). In addition, RAP blunted CML-induced 
nuclear translocation of HIF-1α and its DNA binding activity, nuclear translocation of NFATC1, 
activation of HIF-1α, and up-regulation of IL-6 (Supplementary Figure 3A-B). Proliferation and 
NF-κB nuclear translocation induced by CML were also inhibited by an anti-RAGE antibody in 
MIA PaCa-2 culture (Supplementary Figure 4A-B). 
Expression of the RAGE homolog ALCAM (32) was not detectable (MIA PaCa-2) or at the limit 
of detectability (PANC-1) in PDA cells untreated or treated with CML or CML+RAP for 24 hrs. 
CML favors development and progression of early murine PaC 
After six weeks of CML treatment (i.e., at 11 weeks of age), more than half of KCM mice (6/11) 
showed positive abdominal imaging and ~1/4 (3/11) had a palpable abdominal mass (Figure 3A). 
At this age, only one Ctr-KCM mice showed significant abdominal photon emission 
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(Supplementary Figure 5). Therefore, to avoid loss of CML-treated KCM mice and limit the 
number of animals, the study was stopped at this time. However, since the in vivo imaging does not 
allow to clearly identify the organ/tissue contributing to the BLI signal, we performed ex vivo 
imaging of the gastrointestinal apparatus at the time of the sacrifice, which confirmed that specific 
spots of BLI signals were mainly emitted by the pancreatic mass (Figure 3B). 
At histological analysis, invasive PDA was confirmed in 8/11 (72.7%) CML-treated mice, 
compared with 1/11 (9.1%) Ctr mice (Table 1). Therefore, the majority of Ctr mice showed normal 
pancreatic architecture, though pre-invasive PanINs of various degrees were observed in all 
specimens analyzed (Figure 3C). Conversely, the majority of KCM mice treated with CML 
revealed a diffusely infiltrative PDA with well- and poorly-differentiated areas within the same 
tumor (Figure 3C-D); scattered low and high grade PanINs were also seen, especially at the tumor 
border (Figure 3E). These histological features were also observed in the pancreas from the one Ctr-
KCM mice with invasive PaC, consistently with previous reports (33,34). No liver or lung 
metastases were observed grossly or in serial sections in both groups at this age (Table 1). 
CML increases RAGE protein levels in PanINs and well-differentiated regions of invasive 
PaC of KCM mice 
IHC for RAGE distribution in pancreatic sections of CML-treated KCM mice showed intense 
staining of PanINs, but not of the surrounding acinar tissue (Figure 4A-B). A cytoplasmic granular 
RAGE positivity was also observed in cells of duct-like structures in well-differentiated regions of 
the tumor, but not in surrounding undifferentiated areas (Figure 4C). Also PanINs of Ctr-KCM 
mice were positive for RAGE, though staining intensity was fainter than in CML-treated KCM 
mice and restricted to the apical/lateral border of PanIN cells (Figure 4D). Importantly, dual 
labeling immunofluorescence analysis showed co-localization of RAGE with CML in PanINs of 
CML-treated, but not of Ctr-KCM mice (Figure 4E). 
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Western blot analysis demonstrated higher RAGE levels in pancreatic specimens of CML-treated 
mice with well-differentiated PaC (Figure 4F) and significantly increased p-STAT3 levels in CML-
treated- versus Ctr-KCM mice (Supplementary Figure 6). 
RAP delays PanIN lesion development in Ctr-KCM mice but fails to prevent CML-induced 
PaC promotion and progression 
As assessed by histological analysis, none of the ten KCM mice treated with RAP (Ctr+RAP) 
showed invasive PaC at 11 weeks of age (Table 1). However, quantitative analysis of neoplastic 
ducts showed that the number of low grade and, particularly, high grade PanIN lesions was 
significantly reduced in Ctr+RAP compared with Ctr-KCM mice (Figure 5). 
Conversely, RAP administration did not counteract the promoting effect of CML on pancreatic 
tumorigenesis, as demonstrated by the high rate (6/7 animals, 87.5%) of invasive PaC observed in 
KCM mice treated with CML+RAP (Table 1). What is more, liver and/or lung metastases were 
observed grossly and confirmed by histological examination in 3/7 mice (42.5%) (Table 1 and 
Supplementary Figure 7). 
Finally, Western blot analysis and IHC revealed a sharp increase of the protein level of the 
RAGE homolog CD166/ALCAM in mice treated with CML+RAP versus those receiving CML 
alone, but not in animals given RAP only (Figure 5D-E and Supplementary Figure 8). 
RAP+CML treatment reduces serum levels of sRAGE and increases CML:sRAGE ratio 
As expected, serum levels of CML were increased in KCM mice treated with CML and 
CML+RAP (Figure 6A). Conversely, serum sRAGE levels were strongly reduced by CML 
treatment, and further reduced by the combined CML+ RAP treatment (Figure 6B). As a result, the 
serum CML:sRAGE ratio (i.e., free or no sRAGE-associated CML) was higher in CML+RAP-
treated than in CML-treated KCM mice (Figure 6C). 
Consistently with a role of RAGE in IL-6 production, levels of this cytokine were increased in 
KCM mice treated with CML and were partly reduced by RAP treatment (Figure 6D).  
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Discussion 
This study provides the first experimental evidence that the AGE CML (a) modulates the activity 
of signaling pathways involved in PaC development and stimulates cell proliferation in PDA cell 
lines in a RAGE-dependent manner; and (b) accelerates progression from PanINs to invasive PaC in 
a mouse model of Kras-driven PaC. Our results also support previous data demonstrating a 
permissive role for RAGE in early pancreatic neoplasia (10) and the efficacy of RAGE 
ablation/blockade in delaying PaC development in the presence of physiological levels of AGEs 
(9,10). However, our data argue against the utility of RAGE blockade/inhibition as a therapeutic 
option in conditions characterized by increased circulating AGE levels (22,23). Instead, they 
suggest that lowering AGE formation/level, rather than RAGE blockade, might represent a targeted 
risk reduction therapy for PaC in DM and other conditions characterized by increased AGE 
accumulation. The in vitro experiments demonstrated that CML stimulates proliferation of human 
PDA cell lines through RAGE activation, thus suggesting a role for the AGE/RAGE axis in PaC 
promotion. Several lines of evidence support this interpretation. Firstly, the time- and 
concentration-dependent stimulation of cell proliferation by CML was accompanied by a parallel 
up-regulation of RAGE expression and downstream tumorigenic pathways. Secondly, RAGE 
blockade with RAP counteracted the effects of CML on cell proliferation, NF-kB activation, 
STAT3 phosphorylation and up-regulation of its target genes. Thirdly, the higher was the basal 
expression of RAGE (i.e., MIA PaCa-2 > PANC-1 > HPDE), the larger was the range of CML 
concentration with a positive dose-response relationship for cell growth. This RAGE-dependent 
heterogeneity in the cell proliferative response to different AGE levels might represent one of the 
mechanisms through which DM promotes PaC. In fact, the high concentrations of AGEs 
characterizing DM may favor proliferation of initially transformed cells, which show a high 
expression level of RAGE, as compared to non-transformed cells, exhibiting a low level of this 
receptor. 
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The in vivo studies assessing the effect of CML on early pancreatic carcinogenesis showed that 
this AGE accelerates the development of PaC in KCM mice. Although a considerably degree of 
variability exists in total PaC burden among coeval mice, at 11 weeks of age , both KC (36,42) and 
KCM (38) mice showed a substantial number of PanIN lesions (~30% of pancreatic ducts), most of 
which of low-grade, and usually no invasive lesions. Therefore, the finding of 1/11 Ctr-KCM 
mouse with PaC should be considered as an occasional observation. Conversely, the finding that 
8/11 CML-KCM mice presented with invasive PaC indicates that AGEs markedly accelerate PaC 
development. In addition, the content and distribution of RAGE protein and CML in pancreatic 
lesions strongly support the hypothesis that CML-enhanced tumorigenesis is mediated through 
RAGE expression and activation, in keeping with previous data showing that RAGE expression 
increases in parallel with progression of PanIN lesions in KC mice and is up-regulated in human 
PaC specimens (10). Moreover, the pronounced RAGE staining detected in cells of duct-like 
structures in well-differentiated regions of PaC, but not in the surrounding undifferentiated areas, 
suggests that RAGE is dispensable for subsequent steps of tumor progression. Taken together, these 
data support the hypothesis of a permissive role of RAGE for the progression of PanIN lesions to 
invasive PaC, as previously demonstrated in KC-RAGE knockout mice (10). 
According with this assumption, we were able to demonstrate that RAGE blockade with RAP 
reduced the formation and progression of PanINs in KCM mice, consistent with a previous report in 
a pancreatic orthotopic model (9). However, one of the main aims of our study was to verify the 
hypothesis that blockade of the AGE/RAGE axis might represent a targeted risk reduction therapy 
for PaC in high-risk individual such as those with metabolic disorders  and unhealthy lifestyle 
habits (2,26,43,44), who exhibit elevated circulating levels of AGEs (22,23). Contrary to our 
expectations, and at variance with data from cell culture studies and Ctr-KCM mice, RAGE 
blockade with RAP did not prevent the promoting effect of CML on pancreatic carcinogenesis and 
even favored tumor spreading and metastasis. These findings seem to argue against a role of the 
AGE-RAGE in the tumor-promoting effect of CML. However, two lines of evidence indicate they 
may have been related to two effects of RAP observed only when it was administered in mice with 
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pathological levels of  CML (CML+RAP treatment). Firstly, the CML:sRAGE ratio (i.e., free 
CML) was higher in KCM mice treated with CML+RAP than in those treated with CML alone, a 
finding which suggests that, in the presence of high circulating CML levels, RAP has competed 
with CML for binding to sRAGE, thus reducing the decoy receptor activity of this circulating form 
of RAGE generated by both alternative splicing or ectodomain shedding of full-length RAGE.  The 
resulting higher levels of free CML may have favored CML-induced tumor promotion. This 
interpretation is consistent with the concept that serum sRAGE levels represent a promising 
biomarker and therapeutic target in metabolic and neoplastic disorders (45,46). 
Secondly, the protein levels of the RAGE homolog CD166/ALCAM (32) were higher in PaC 
specimens from KCM mice treated with CML+RAP than in those receiving only CML (and also 
those treated with RAP only). This finding suggests that, again only in the presence of high 
circulating levels of  CML, RAGE blockade has resulted in AGE-induced up-regulation of 
CD166/ALCAM and/or favored the clonal expansion of PaC cells expressing this RAGE homolog 
(32). The finding that neither CML nor CML+RAP treatments of PDA cells for 24 hrs were able to 
modify basal ALCAM mRNA expression indicates that this is a gradual process involving in vivo 
tumor heterogeneity and clone selection. This interpretation is consistent with the observation that 
CD166/ALCAM shares with RAGE some endogenous ligands and is compensatory up-regulated 
after genetic deletion of its counterpart (32). In addition, it is supported by the finding that increased 
tumor levels of CD166/ALCAM in KCM mice treated with CML+RAP were associated with tumor 
spread, in keeping with the notions that this RAGE homolog is typically restricted to subsets of 
cells involved in dynamic growth and migration (47) and is an independent prognostic marker for 
poor survival and early tumor relapse in PaC (48). However, the findings in mice treated with 
CML+RAP should be confirmed in mice knockout for RAGE treated with CML, though, in our 
hands, RAP treatment provided similar protective effects to those induced by RAGE ablation in 
mice not treated with CML (10). Another limitation of our study is the lack of use of analytical 
techniques to confirm data on CML serum levels obtained by ELISA, though immunological and 
analytical methods were shown to produce comparable results in similar conditions (49). 
18 
 
In summary, our data demonstrate that the AGE/RAGE axis modulates PaC development in a 
genetically-engineered mouse model of the disease, as shown by the acceleration of PanIN 
progression to PaC and the concurrent up-regulation of RAGE expression induced by the AGE 
CML. This finding provides a conceivable molecular mechanism to explain the increased risk of 
PaC conferred by DM and other conditions of increased AGE accumulation. However, RAGE 
blockade with RAP was ineffective, if any, in protecting from CML-induced promotion of 
tumorigenesis, likely due to competition with sRAGE for binding to AGEs and compensatory up-
regulation of CD166/ALCAM and/or clonal expansion of tumor cells expressing this RAGE 
homolog. Taken together, these results suggest that an AGE reduction strategy might be more 
suitable than RAGE blockade to reduce the PaC risk associated with DM, obesity, western diet and 
tobacco smoking. 
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Table 1.  Pancreatic cancer (PaC) prevalence rate in KCM mice treated with MSA (Ctr), CML-
modified MSA (CML), MSA plus RAP (Ctr+RAP) and CML plus RAP (CML+RAP) after 6 weeks 
of treatment (11 weeks of age). 
 
Treatment PaC 
N/tot 
PaC 
% 
P value Metastasis 
N/tot 
Ctr 1/11 9.1 — 0/11 
CML 8/11 72.7 0.00752 0/11 
Ctr+RAP 0/10 0 1 0/10 
CML+RAP 6/7 85.7 0.00245 3/7 
2 liver and 1 lung 
 
KCM = LSL-KrasG12D/+;Pdx-1-Cre;MITO; MSA = mouse serum albumin; CML = Nε-
carboxymethyllysine; RAP = RAGE antagonist peptide. N/tot = number of cases/total number of 
mice. P value = two-tailed P value for the difference in PaC rate vs. Ctr mice obtained from the 
Fisher's exact test. 
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Figure legends 
Figure 1. CML induces PDA cell proliferation and RAGE up-regulation in a concentration- 
and time-dependent manner. Concentration (A) and time dependent (B) cell proliferation and 
RAGE expression in Mia PaCa-2 cells exposed to native HSA (Ctr) or CML-modified HSA (CML). 
Time dependent cell proliferation and RAGE expression in PANC-1 (C) and HPDE (D) exposed to 
10 μg/ml of HSA or CML for 24 hrs, and relative representative images. Basal RAGE mRNA 
expression levels in Mia PaCa-2, PANC-1 and HPDE cells, as assessed by qRT-PCR (E). n = 5 
wells per condition. Post-hoc multiple comparison: *P<0.01 vs. HSA; †P<0.001 vs. Mia PaCa-2; 
#P<0.001 vs. PANC-1. Dashed double arrow = range of CML concentration with a positive dose-
response relationship for cell proliferation at 24 hrs. 
Figure 2.  CML activates the NF-κB/STAT3/Pim1/NFAT axis through RAGE signaling in 
PDA cell lines. Western blot for p65 NF-κB subunit and p-STAT3 protein expression in Mia PaCa-
2 cells exposed to native HSA (Ctr), CML-modified HSA (CML) or CML+RAP at the 
concentration indicated for 24 and 48 hrs and relative band densitometry analysis from three 
separate experiments (A). NF-κB/p65 activity of the nuclear extracts assessed by ELISA (B). PIM1 
and NFATC1 mRNA expression (C) and cell proliferation (D) in MIA PaCa-2 cells exposed to 50 
μg/ml of HSA or CML, and 50 μg/ml of CML plus RAP 10 μmol/L for 24 hrs; n = 3 wells per 
condition. Post-hoc multiple comparison: *P< 0.01 vs. HSA; †P< 0.001 vs CML. 
Figure 3. BLI and pancreatic histological analysis in Ctr and CML-treated KCM mice. In vivo 
(A, total body) and ex vivo (B, middle part of the gastrointestinal tract including the pancreas) BLI 
from a Ctr, tumor-free KCM mouse, and a CML-treated KCM mouse with invasive PaC, as 
assessed by histology. Different light emissions are highlighted with pseudo-colors based on the 
reported pseudo color scale, expressed in units of photon/second/cm2/steradian (p/s/cm2/sr). The 
corresponding histology of pancreatic sections stained with H&E (C): ten of eleven Ctr-KCM mice 
show normal pancreas histology of both acinar and islet (is) compartments, though PanINs (arrow) 
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of various degree were detected in all specimens analyzed (C, Ctr). The histological analysis of the 
pancreas from the majority (eight of eleven) of CML-treated KCM mice demonstrated a diffusely 
infiltrative adenocarcinoma (C, CML) with well (D, to the right of the dashed line) and poorly 
differentiated (D, to the left of the dashed line) regions within the same tumor. Scattered low and 
high grade PanINs (arrows) are recognizable, especially at the junction between normal acini (right 
part of panel E) and invasive PaC (left part of panel E). Scale bar = 100µm. 
Figure 4. RAGE protein levels and tissue distribution and co-localization with CML in Ctr 
and CML-treated KCM mice. Intense positive staining for RAGE in PanINs (arrows) of CML-
treated KCM mice (A); at higher magnification, intense positive staining on apical surface of 
columnar epithelial cells is observed, although a strong cytoplasmic granular positivity can also be 
appreciated (B). RAGE staining is also detectable in cells of duct-like structures in well-
differentiated regions of the tumor (C), but not in surrounding undifferentiated areas (asterisks). 
Finally, faint staining for RAGE is also seen in PanINs (arrows) of Ctr-KCM mice (D). Scale bar = 
100µm. Dual label immunofluorescence analysis shows positive staining for CML (green) and co-
localization (yellow in the merged image) with RAGE (red) in PanIN lesions of CML-treated KCM 
mice. Conversely, in PanINs of Ctr-KCM mice CML is only barely detectable, whereas RAGE 
positivity, albeit fainter, is observable at the cell borders. Corresponding light microscopy images 
(H&E staining) have been included. Blue = DAPI (E). Representative Western blot (lower box) for 
RAGE protein expression in three tumor-free Ctr and three CML-treated KCM mice showing well-
differentiated PaC at the histological examination (F); the upper box shows the acquisition of total 
protein content after Stain-Free gel exposure to ultraviolet light and protein transfer onto a 
nitrocellulose membrane. 
Figure 5. PanINs in Ctr and Ctr+RAP KCM mice, and CD166/ALCAM protein levels in Ctr 
and CML-KCM mice treated or untreated with RAP. Percentages of normal (ND) and 
neoplastic ducts (LG and HG) by grade in ten Ctr (excluding the only Ctr mouse with PaC), and ten 
RAP-treated KCM mice (A). LG (low grade) = PainIN-1A plus 1B lesions; HG (high grade) = 
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PainIN 2 plus 3 lesions. Two-tailed test: *P< 0.001 vs. Ctr.  Examples of HG PanINs-2 and 3 from 
a Ctr-KCM mouse (B): PanIN-2 lesion (left) with papillary architecture, revealing moderate loss of 
polarity, nuclear crowding and atypia; PanIN-3 lesion (right) shows more severe nuclear atypia, loss 
of polarity and budding off of small clusters of epithelial cells (arrow) into the lumen of the duct. 
Examples of LG PanINs-1A and 1B from a RAP-treated KCM mouse (C): three PanINs-1A 
(arrowheads) with a flat epithelial pattern, composed of tall columnar cells with basally located 
nuclei and abundant mucin content; PanIN-1B lesion (arrow) has similar cytological features but 
reveals a papillary/pseudostratified architecture. Representative Western blot for CD166/ALCAM 
in Ctr, CML, CML+RAP and Ctr+RAP-treated KCM mice and relative band densitometry analysis 
from seven mice per group (D). Normalization of the protein input was performed using the Stain-
Free technology: after ultraviolet exposure of Stain-Free gel, proteins were transferred onto a 
nitrocellulose membrane and ultraviolet light-induced tryptophan fluorescence from the entire lane 
(i.e., total protein content) was measured; Stain-Free membrane for Western blot normalization is 
shown in Supplementary Fig. 5. CD166/ALCAM staining pattern in PaC from CML and 
CML+RAP-treated KCM mice (E); note the intense staining for CD166/ALCAM in the clusters of 
cells floating into the lumen of the duct-like structures (arrow) of CML+RAP-treated mice. Cells of 
surrounding undifferentiated areas were also positive for CD166/ALCAM (asterisk).  Scale bar = 
100µm. Post-hoc multiple comparison: *p<0.01 or **p<0.001 vs. Ctr; †p<0.01 vs. CML. 
Figure 6. Serum levels of the AGE CML, sRAGE and IL-6. Serum levels of CML (A) and 
sRAGE (B), ratio of serum levels of AGEs to sRAGE (C) and IL-6 serum levels (D) in Ctr (n0 11), 
CML (n=11) and CML+RAP-treated (n=7) KCM mice. Post-hoc multiple comparison: *P< 0.01 
and **P<0.001 vs. Ctr; †P<0.05 and ††P<0.01 vs. CML. 
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Supplementary Methods 
Reference numbers refer to the main text list 
In vitro studies 
Preparation and characterization of Nε-(Carboxymethyl)Lysine (CML)-modified serum albumin 
CML was prepared as previously reported [21,29]. Briefly, 175 mg human (HSA) or mouse (MSA) 
serum albumin (Sigma-Aldrich, St.Louis, MO, USA) were incubated in 1 ml of 0.2 M phosphate 
buffer, pH 7.8, containing 0.15 M glyoxylic acid (Sigma-Aldrich) and 0.45 M sodium 
cyanoborohydrate (Acros Organics, Morris Plains, NJ, USA) for 24 h at 37°C. Preparations of 
CML-modified albumin were extensively dialyzed versus phosphate-buffered saline (PBS) for 48 h 
using Cellu Sep H1 tubular membranes MWCO 15,000 (Orange Scientific, Braine l’Alleud, 
Belgium) purified several times through endotoxin-removing columns High Capacity Endotoxin 
Removal Spin Column, (Thermo Scientific, Rockford, IL, USA), passed through 22 μm filters, and 
assessed for endotoxin content by the Limulus amoebocyte lysate test kit (Sigma-Aldrich). Protein 
concentration was assessed by the Bradford assay (Bio-Rad, Hercules, CA, USA). The extent of 
murine (MSA) and human (HSA) lysine modification was determined by employment of 2,4,6-
trinitrobenzenesulfonic acid (TNBSA) (Thermo Fisher Scientific, Waltham, MA, USA), according 
to manufacturer’s instructions. Briefly, 250μl of TNBSA solution were added to 500 μl of each 
sample. After incubation at 37°C for two hours, the reaction was terminated by adding 250 μl of 
10% SDS and 125 μl of 1N HCl followed by measurement of absorbance at 420 nm. The standard 
curve generated by unmodified HSA or MSA was used as the calibration standard.  
 
RAGE neutralization 
In order to evaluate the actual contribution of advanced glycation endproducts receptor (RAGE) in 
the cellular effects induced by CML-modified albumin, cells were treated with an anti-RAGE 
antibody to neutralize the RAGE receptors prior to CML challenge. The immunologic strategy was 
preferred to the RNA interference one because RNA-mediated gene silencing may induce non-
specific or off-target effects such as NF-κB activation, which in turn may affect tumor cell survival 
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[50]. Briefly, MiaPaCa2 cells were incubated for one hour with 10 μg/mL anti-RAGE antibody 
(PA5-24787, Thermo Fisher Scientific) directed to the V domain of the N-terminal region of 
RAGE, which is the extracellular domain involved in RAGE ligation by CML [28], or 10 μg/mL 
IgG isotype control (#10500C Thermo Fisher Scientific). Then, cells were treated with 50 μg/ml 
CML for 24 h prior to evaluate cell proliferation by cell count and the DNA-binding activity of NF-
κB/p65 by the TransAM NFkB p65 kit (Active Motif Corp., Carlsbad, CA, USA). Each condition 
was done in triplicate, and the experiment was repeated 3 times. 
 
In vitro analysis of the binding of RAGE to immobilized CML-MSA 
To confirm RAGE binding to the CML-MSA preparation, we measured its binding ability in a 
functional ELISA, as previously reported by Rao et al [51]. Polyvinyl 96-well plates were coated 
with 0.5 µg/well of CML-MSA or native MSA as negative control. Next, 50 µl of 0.25, 0.5 and 1 
nM recombinant mouse RAGE provided as standard with the ELISA kit for sRAGE (#893192, 
R&D Systems, Minneapolis, MN, USA) were added to each CML-MSA or native MSA-coated 
well and incubated at 37°C for 1 h. To detect bound RAGE, 50 µl of the polyclonal antibody 
specific for mouse RAGE conjugated to horseradish peroxidase provided with the same kit 
(#893191, R&D Systems) was added to each well and the mixture was incubated for 1 h at room 
temperature. Color reagent A (#895000, R&D Systems) and B (#895001, R&D Systems) were 
added, reaction stopped with stop solution (#895174, R&D Systems) and the colorimetric reaction 
was evaluated by reading absorbance at 450 nm using an automated microplate reader (Varioskan 
Lux, Thermo Fischer Scientific). 
 
In vivo studies 
Generation of the transgenic animal model 
The LSL-KrasG12D/+ lineage was maintained in the heterozygous state. Mice were screened by PCR 
using tail DNA amplified by specific primers to the Lox-P cassette flanking mutated KrasG12D/+, 
wild type Kras, Cre recombinase and MITO genes (Supplementary Table S3). 
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In the MITO-Luc mouse, an artificial minimal promoter derived from the cyclin B2 gene and 
induced by NF-Y drives the expression of the luciferase reporter specifically in proliferating cells, 
which may therefore be localized by a bioluminescence imaging (BLI)-based screen [37,38]. We 
have previously shown that KCM mice develop pre-invasive (PanIN) and invasive ductal PaC with 
the same penetrance, latency and histological features as those described for KC mice [38]. 
 
RAGE and CML pancreatic tissue distribution  
Pancreatic tissue distribution and co-localization of RAGE and CML were evaluated 
immunohistochemically [29,52] by dual label immunofluorescence [52] using a goat polyclonal 
antibody to amino acids 42-59 of human RAGE (ab7764, Abcam, Cambridge, UK ), and a mouse 
monoclonal antibody against CML (ab27685, Abcam), as primary antibodies. Then, an Alexa 
Fluor®594 chicken anti-goat IgG H&L (Invitrogen, Carlsbad, CA, USA) and a DyLight®488 anti-
mouse IgG H&L (Vector Labs, Burlingame, CA, USA) were used as secondary antibodies (52). 
Sections were analyzed at a fluorescence microscope (Zeiss AXIO A1), equipped with an Axiocam 
503 color camera (Carl Zeiss Italy, Milan, Italy). 
 
TGX Stain-Free technology for total protein measurement 
For Western blot analysis, proteins were separated on a TGX Stain-Free Gel (Bio-Rad laboratories) 
and activated by a 2 min ultraviolet exposure using the ChemiDoc XRS+ Imager (Bio-Rad 
laboratories). After protein transfer, membranes were imaged for Stain-Free staining and total 
proteins in each lane were quantified using the ImageLab 5.2 software (Bio-Rad laboratories) and 
normalized using Stain-Free technology (Bio-Rad laboratories). This approach was preferred to the 
use of an internal standard due to the poor reliability of housekeeping proteins, which showed 
significant variations, especially between samples with and without invasive neoplastic disease. 
 
Validation of ELISA kits for the determination of sRAGE and CML serum levels 
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In order to verify whether the presence of CML in the assay system could affect sRAGE data 
obtained by ELISA, CML-MSA was added to pooled serum from three Ctr mice at a final 
concentration of 300, 600, or 900 ng/ml prior to assess sRAGE level with mouse sRAGE ELISA kit 
(R&D Systems). The same pooled serum with equal volume of PBS added was used as control. The 
same procedure was used to evaluate the potential interference of the RAGE antagonist peptide 
(RAP) with sRAGE data. In this case, RAP (Calbiochem, Merck KGaA, Darmstadt, Germany) was 
added to pooled serum at a final concentration of 5, 10, or15 μM. The range of final concentrations 
of CML-MSA was comparable to that of CML serum levels detected in CML-treated KCM mice, 
whereas that of RAP comprised the concentration used in the in vitro experiments (10 μM), which 
was shown to be able to block RAGE activity. We also verified whether the presence of sRAGE or 
RAP in the CML assay system could affect CML data obtained by ELISA. For this purpose, RAGE 
(#893192, R&D Systems) or RAP were added to pooled serum from three CML mice prior to 
assessing CML levels with CML ELISA kit (R&D Systems). The final concentration of RAGE was 
100, 300, or 600 pg/ml, i.e., within the range of circulating RAGE levels detected in mice. The final 
concentration of RAP was 5, 10, or15 μM, as reported above. The same pooled serum with equal 
volume of PBS added was used as control. 
  
43 
 
Table S1.  TaqMan Gene Expression assays 
 
Target Assay 
AGER Hs00153957_m1 
ALCAM Hs00977641_m1  
NFATC1 Hs00542678_m1  
PIM1 Hs01065498_m1  
IL6 Hs00174131_m1 
 
AGER = receptor for advanced glycation endproducts; ALCAM = activated leukocyte cell adhesion 
molecule; NFATC1 = nuclear factor of activated T-cells cytoplasmic 1; PIM1 = serine/threonine-
protein kinase Pim-1; IL6 = interleukin-6. 
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Table S2.  Antibodies used in Western blot and IHC studies. 
Target Antibody Catalog Nr. Supplier 
Primary    
NF-κB subunit 
p65 
mouse monoclonal F-6 SC8008 Santa Cruz  Biotechnology, Dallas, 
TX, USA 
(p)STAT3 rabbit polyclonal 9131S Cell Signaling Technology, Danvers, 
MA, USA 
STAT3 rabbit monoclonal 
79D7 
4904 Cell Signaling Technology, Danvers, 
MA, USA 
NFATC1 mouse monoclonal MAB3209 Abnova, Taipei City, Taiwan 
HIF-1α rabbit monoclonal ab51608 Abcam, Cambridge, UK 
RAGE (IHC) goat polyclonal ab7764 Abcam, Cambridge, UK 
RAGE (WB) rabbit polyclonal PA5-24787 Thermo Fisher Scientific, Waltham, 
MA, USA 
CML goat polyclonal ab27685 Abcam, Cambridge, UK 
CD166/ALCAM 
(WB & IHC) 
rabbit monoclonal 
EPR2759(2) 
ab1092015 Abcam, Cambridge, UK 
Secondary    
HIF-1α, RAGE 
(WB), CD166/ 
ALCAM (WB) 
HRP-conjugated goat 
anti-rabbit 
P0448 Agilent/Dako, Santa Clara, CA, 
USA 
NF-κB subunit 
p65, NFATC1 
HRP-conjugated goat 
anti-mouse HRP 
conjugated 
P0447 Agilent/Dako, Santa Clara, CA, 
USA 
RAGE (IHC/IP) Biotinylated rabbit anti-
goat IgG 
ab6740 Abcam, Cambridge, UK 
CD166/ALCAM 
(IHC) 
Biotinylated goat anti-
rabbit IgG 
E0432 Agilent/Dako, Santa Clara, CA, 
USA 
RAGE (IHC/IF) Alexa Fluor® 594 
chicken anti-goat IgG 
A-21468 Invitrogen, Carlsbad, CA, USA 
CML  DyLight®488 horse 
anti-goat IgG 
DI-3088 Vector Laboratories, Burlingame, 
CA, USA 
 
WB = Western blot; IHC = immunohistochemistry; NF-κB = nuclear factor-κB; p-STAT3 = 
phosphorylated Signal Transducer and Activator of Transcription 3; NFATC1 = nuclear factor of 
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activated T-cells cytoplasmic 1; HIF-1 = hypoxia-inducible factor 1; RAGE = receptor for advanced 
glycation endproducts; CML = Nε-carboxymethyl lysine; ALCAM = activated leukocyte cell 
adhesion molecule; IP = immunoperoxidase; IF = immunofluorescence. 
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Table S3.  Primers for genotyping. 
 
Gene Oligonucleotide Primer 
Kras Oligonucleotide 1: 
Oligonucleotide 2: 
Oligonucleotide 3: 
5’-GTCTTTCCCCAGCACAGTGC; 
5’-CTCTTGCCTACGCCACCAGCTC; 
5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA. 
Pdx-1-
Cre 
Oligonucleotide up: 
Oligonucleotide 
down: 
5’-ATGCTTCTGTCCGTTTGCCG; 
5’-TGAGTGAACGAACCTGGTCG. 
MITO Oligonucleotide up: 
Oligonucleotide 
down: 
5’-
TGTAGACAAGGAAACAACAAAGCCTGGTGGCC; 
5’-GGCGTCTTCCATTTTACCAACAGTACCGG. 
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Supplementary Figures 
Figure S1. Analysis of the binding of RAGE to immobilized CML-MSA in a functional ELISA. 50 
µl of 0.25, 0.5 and 1 nM of mouse RAGE/Fc chimera were added to wells coated with 0.5 µg of 
CML-MSA or native MSA and incubated at 37°C for 1 h. RAGE bound immobilized CML-MSA in 
a dose-dependent manner, at variance with native MSA. Data are means±SD of triplicate wells for 
each concentration of mouse RAGE/Fc chimera. Two-tailed test: *P< 0.001 vs. MSA.  
  
48 
 
Figure S2. Validation of the ELISA kits for the determination of sRAGE and CML serum levels. 
Data on serum sRAGE (A,B) levels detected by ELISA in pooled serum from three Ctr mice were 
not affected by the addition of increasing amounts of CML (A) or RAP (B) in the assay system. 
Likewise, serum CML levels (C,D) detected by ELISA in pooled serum from three CML mice were 
not affected by the addition of increasing amounts of sRAGE (C) or RAP (D). Data are means±SD 
of triplicate wells per condition. 
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Figure S3. HIF-1α and NFATc1 nuclear protein levels, HIF-1α DNA-binding activity and IL-6 
mRNA expression in Mia PaCa-2 cells. (A) Representative Western blot for NFATc1 and HIF-1α 
nuclear protein levels in Mia PaCa-2 cells exposed to native HSA (Ctr), CML-modified HSA 
(CML) or CML+RAP at the concentration indicated for 24 h and relative band densitometry 
analysis from three separate experiments. (B) ELISA for DNA-binding activity of HIF-1α and IL6 
mRNA expression  in Mia PaCa-2 cells exposed to 50 µg/ml of HSA or CML, and 50 µg/ml CML 
plus 10 μmol/L of RAP for 24 h. Nuclear extract from HeLa cells treated with CoCl2 is provided as 
positive control for HIF-1 activation by the manufacturer. Data represent three separate 
experiments. Post-hoc multiple comparison: *P< 0.05, **P<0.01 and ***P<0.001 vs. HSA; 
†P<0.05 ††P<0.01 and †††P<0.001 vs. CML. 
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Figure S4. Activation of NF-κB/p65 and PDA cell proliferation induced by CML is dependent on 
interaction with RAGE. (A) NF-κB/p65 activity of the nuclear extracts assessed by ELISA  and (B) 
cell proliferation  in MIA PaCa-2 cells incubated for one hour with 10 μg/mL anti-RAGE antibody 
or 10 μg/mL IgG isotype control and exposed to 50 μg/ml of CML for 24h; n = 3 wells per 
condition. Post-hoc multiple comparison: *P<0.001 vs. HSA; †P< 0.01 vs CML + IgG control. 
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Figure S5. In vivo BLI signal quantification in 11-week-old Ctr and CML-treated mice. Box plots 
represent in vivo BLI signal quantification in Ctr (n=11) and CML-treated (n=11) KCM mice. Data 
were expressed as photon/second/cm2/steradiant (p/s/cm2/sr). 
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Figure S6. Pancreatic protein levels of phospho (p)-STAT3. Representative Western blot for 
STAT3 protein phosphorylation in three Ctr and three CML-treated KCM mice and relative band 
densitometry analysis from five mice per group. The membrane used for RAGE detection was 
reprobed with anti-STAT 3 antibody after stripping. Therefore, normalization for total protein 
content was performed on the same Stain-Free gel (upper box) used for RAGE normalization (see 
Figure 4E). The lower boxes show acquisition of the immunoreactive p-STAT3 and total STAT3 
bands. Two-tailed test: *P< 0.001 vs. Ctr. 
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Figure S7. Liver and lung metastasis in KCM mice treated with CML+RAP. (A) A large, well 
differentiated liver metastasis. Cells were arranged in ductal-like structures (arrows). CV = central 
vein. (B) Lung, undifferentiated metastasis surrounded by dashed line. Scale bar = 100µm 
.  
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Figure S8. Stain-free membrane image for protein loading normalization relative to 
CD166/ALCAM Western blot. Acquisition of total protein content after Stain-Free gel exposure to 
ultraviolet light and protein transfer onto a nitrocellulose membrane for CD166/ALCAM Western 
blot normalization (see Figure 5D). 
 
